Market Overview

UPDATE: Jefferies Initiates AbbVie at Buy on Growth Outlook, High Yield

Share:
Related ABBV
Abbvie Announces Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA
AbbVie Announces NEJM Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia
Buy AbbVie Incorporated: Its Frustration Is Your Long-Term Gain (Seeking Alpha)

Jefferies initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and a $44.00 price target.

Jefferies commented, "AbbVie is our top pick for 2013. We see the initial trading volatility post-spin as an opportune entry point into the shares as we soon expect income funds to work the dividend yield down to at least the 4.0% level. A more durable long-term performance from Humira, stronger pipeline delivery and operating margin expansion drive our cash EPS estimates up to 22% ahead of consensus."

AbbVie closed at $34.09 on Tuesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Sep 2016JP MorganDowngradesOverweightNeutral
Sep 2016Raymond JamesInitiates Coverage onOutperform
Jun 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!